Frederico Xavier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Frederico Xavier has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Meghan McCormick
Division of Pediatric Hematology‐Oncology University of Miami Miller School of Medicine Miami Florida USA
2 shared publicationsAbdallah Abdallah
1 shared publication- Adam Kirton
Department of Pediatrics University of Calgary Calgary Alberta Canada
1 shared publication Alexandra Linds
Division of Neurology, Child Health Evaluative Sciences Program, The Hospital for Sick Children, Toronto, Ontario, Canada
1 shared publication- Allison P. Wheeler
Division of Pediatric Hematology, Oncology, Bone Marrow Transplant, and Cellular Therapy, University of Washington, Seattle, WA
1 shared publication Amanda Blair
1 shared publication
Latest Publications
- 23 July 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (10) , e31927
Targeted Treatment With Alpelisib for Papillary Intralymphatic Angioendothelioma Associated With Somatic PIK3CA Mosaicism
- 23 July 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (10) , e31927
Targeted Treatment With Alpelisib for Papillary Intralymphatic Angioendothelioma Associated With Somatic PIK3CA Mosaicism
- Open Access
- 25 May 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (8) , e31816
Patterns of Direct Oral Anticoagulant Use in Pediatric Patients: Results From a Multicenter National Database
Background: Direct oral anticoagulants (DOACs) have quickly gained favor due to oral availability, favorable risk profile, and reduced lab monitoring. This study aims to evaluate trends in DOAC use among pediatric patients with new venous thrombotic events (VTE) and factors associated with their selection.Procedure: This was a retrospective study using the Pediatric Health Information System (PHIS) administrative database. We included initial inpatient encounters from 2014 to 2021 for children (age 0–18 years) with an ICD‐9 or ICD‐10 code for VTE. We compared characteristics of patients who received DOACs to those who did not, through descriptive and statistical analysis and evaluated factors associated with DOAC selection with logistic regression.Results: In 20,332 cases of new VTE, DOACs were administered in 810 encounters (3.98%), most commonly rivaroxaban (75.1% of cases). DOAC use increased over time to 12.0% of encounters in 2021. Patients who received DOACs had greater median age (16 vs. 4 years, p < 0.001), were more commonly female (51.6% vs. 46.7%, p = 0.007), had greater median income ($64,908 vs. $57,165, p < 0.001), and were more likely to carry private insurance (47% vs. 41%, p = 0.003). Patients who received DOACs had lower average hospitalization duration, hospitalization costs, and were less likely to have a complex chronic condition. On regression analysis, factors associated with DOAC use included older age, increased income, and geographic region (p < 0.05).Conclusions: DOACs are increasingly used in pediatric patients. Decision‐making appears to be affected by patient age, medical comorbidities, and income, suggesting prescription trends may not be based on clinical evidence alone.
- 25 May 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (8) , e31816
Open AccessPatterns of Direct Oral Anticoagulant Use in Pediatric Patients: Results From a Multicenter National Database
Background: Direct oral anticoagulants (DOACs) have quickly gained favor due to oral availability, favorable risk profile, and reduced lab monitoring. This study aims to evaluate trends in DOAC use among pediatric patients with new venous thrombotic events (VTE) and factors associated with their selection.Procedure: This was a retrospective study using the Pediatric Health Information System (PHIS) administrative database. We included initial inpatient encounters from 2014 to 2021 for children (age 0–18 years) with an ICD‐9 or ICD‐10 code for VTE. We compared characteristics of patients who received DOACs to those who did not, through descriptive and statistical analysis and evaluated factors associated with DOAC selection with logistic regression.Results: In 20,332 cases of new VTE, DOACs were administered in 810 encounters (3.98%), most commonly rivaroxaban (75.1% of cases). DOAC use increased over time to 12.0% of encounters in 2021. Patients who received DOACs had greater median age (16 vs. 4 years, p < 0.001), were more commonly female (51.6% vs. 46.7%, p = 0.007), had greater median income ($64,908 vs. $57,165, p < 0.001), and were more likely to carry private insurance (47% vs. 41%, p = 0.003). Patients who received DOACs had lower average hospitalization duration, hospitalization costs, and were less likely to have a complex chronic condition. On regression analysis, factors associated with DOAC use included older age, increased income, and geographic region (p < 0.05).Conclusions: DOACs are increasingly used in pediatric patients. Decision‐making appears to be affected by patient age, medical comorbidities, and income, suggesting prescription trends may not be based on clinical evidence alone.
- 1 January 2018
- Published by Elsevier in Pediatric Neurology
- Vol. 78, 46-54
Dyslipidemia in Children With Arterial Ischemic Stroke: Prevalence and Risk Factors
- 1 January 2018
- Published by Elsevier in Pediatric Neurology
- Vol. 78, 46-54
Dyslipidemia in Children With Arterial Ischemic Stroke: Prevalence and Risk Factors